Ascites Pipeline Analysis Report 2025
Description
Ascites is the abnormal buildup of fluid in the abdominal cavity, commonly linked to liver cirrhosis, heart failure, or cancer. According to Mengying Xu et al., 2024, malignant ascites accounts for approximately 10% of all ascites cases. Current therapies include diuretics, paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS). According to the ascites pipeline analysis by Expert Market Research, growing research focuses on targeted therapies and biologics aimed at improving patient outcomes. Rising liver disease prevalence and oncology advancements are expected to drive significant growth in the ascites treatment landscape in the coming years.
Report Coverage
The Ascites Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ascites therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ascites. The ascites report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ascites pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ascites treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ascites.
Ascites Pipeline Outlook
Ascites is the abnormal accumulation of fluid in the peritoneal cavity, usually caused by severe liver disease such as cirrhosis. It occurs when portal hypertension and low albumin levels disrupt fluid balance, leading to fluid leakage from blood vessels into the abdominal cavity.
Ascites treatment focuses on reducing fluid buildup and relieving discomfort. The common approaches include diuretics, paracentesis, sodium restriction, and advanced options like transjugular intrahepatic portosystemic shunt (TIPS) or implantable medical devices. In December 2024, Sequana Medical announced the United States Food and Drug Administration approval of alfapump®, a breakthrough implantable device for recurrent or refractory ascites due to liver cirrhosis. The device automatically transfers excess abdominal fluid to the bladder, reducing the need for paracentesis and improving patients’ quality of life.
Ascites Epidemiology
According to Mengying Xu et al. (2024), gastric cancer accounts for a significant proportion of malignant ascites cases, with peritoneal metastasis observed in over 50% of patients with distant metastasis. Malignant ascites represents approximately 10% of all ascites cases. Paul Carrier et al. (2024) reported that liver cirrhosis causes about 85% of ascites cases, followed by cancer at 7%, with the remaining cases linked to heart, kidney, or multiple underlying conditions.
Ascites – Pipeline Therapeutic Assessment
This section of the report covers the analysis of ascites drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
The ascites pipeline analysis report covers 50+ drug analyses based on drug classes:
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total ascites clinical trials (at 51%) reflecting strong progress in mid-stage clinical developments for ascites treatment. Phase I accounts for 34%, indicating steady early-stage research activities. Phase III represents 14%, showcasing ongoing advanced trials. Collectively, these phases highlight growing innovation and potential breakthroughs driving advancements in the ascites market.
Ascites Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the ascites pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The ascites report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ascites. Vasopressin receptor modulators are emerging as a promising drug class in the ascites treatment pipeline. For example, Ocelot Bio’s OCE-205, a mixed vasopressin 1a receptor agonist-antagonist peptide, has received orphan drug designation from the United States Food and Drug Administration for the treatment of ascites. The therapy aims to reduce portal hypertension and improve ascitic fluid volume in patients with advanced liver disease.
Ascites Clinical Trials – Key Players
The EMR report for the ascites pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ascites therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ascites clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ascites. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ascites drug candidates.
Drug: M701
M701 Bispecific Antibody, developed by Wuhan YZY Biopharma Co., Ltd., is under evaluation in a Phase III clinical trial to determine its efficacy and safety in treating malignant ascites caused by advanced epithelial solid tumors. This recombinant human-mouse chimeric antibody targets EpCAM on tumor cells and CD3 on T cells, facilitating immune-mediated tumor destruction. The study is examining M701’s ability to extend puncture-free survival and reduce fluid accumulation, aiming to improve overall patient outcomes.
Drug: VS-01
VS-01 is an innovative liposomal formulation developed by Versantis AG to treat patients with acute-on-chronic liver failure (ACLF) and ascites. In this Phase 2, multi-center, randomized, open-label study (UNVEIL-IT®), the drug is being evaluated for its efficacy, safety, and tolerability when administered intraperitoneally once daily for four days. The study is examining whether VS-01, combined with standard care, is improving clinical outcomes compared to standard therapy alone.
Key Questions Answered in the Ascites Pipeline Insight Report
The Ascites Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ascites. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ascites collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Ascites Market Size, Share Analysis and Forecast Report
Ascites Epidemiology Forecast
Report Coverage
The Ascites Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ascites therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ascites. The ascites report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ascites pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ascites treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ascites.
Ascites Pipeline Outlook
Ascites is the abnormal accumulation of fluid in the peritoneal cavity, usually caused by severe liver disease such as cirrhosis. It occurs when portal hypertension and low albumin levels disrupt fluid balance, leading to fluid leakage from blood vessels into the abdominal cavity.
Ascites treatment focuses on reducing fluid buildup and relieving discomfort. The common approaches include diuretics, paracentesis, sodium restriction, and advanced options like transjugular intrahepatic portosystemic shunt (TIPS) or implantable medical devices. In December 2024, Sequana Medical announced the United States Food and Drug Administration approval of alfapump®, a breakthrough implantable device for recurrent or refractory ascites due to liver cirrhosis. The device automatically transfers excess abdominal fluid to the bladder, reducing the need for paracentesis and improving patients’ quality of life.
Ascites Epidemiology
According to Mengying Xu et al. (2024), gastric cancer accounts for a significant proportion of malignant ascites cases, with peritoneal metastasis observed in over 50% of patients with distant metastasis. Malignant ascites represents approximately 10% of all ascites cases. Paul Carrier et al. (2024) reported that liver cirrhosis causes about 85% of ascites cases, followed by cancer at 7%, with the remaining cases linked to heart, kidney, or multiple underlying conditions.
Ascites – Pipeline Therapeutic Assessment
This section of the report covers the analysis of ascites drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
The ascites pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total ascites clinical trials (at 51%) reflecting strong progress in mid-stage clinical developments for ascites treatment. Phase I accounts for 34%, indicating steady early-stage research activities. Phase III represents 14%, showcasing ongoing advanced trials. Collectively, these phases highlight growing innovation and potential breakthroughs driving advancements in the ascites market.
Ascites Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the ascites pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The ascites report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ascites. Vasopressin receptor modulators are emerging as a promising drug class in the ascites treatment pipeline. For example, Ocelot Bio’s OCE-205, a mixed vasopressin 1a receptor agonist-antagonist peptide, has received orphan drug designation from the United States Food and Drug Administration for the treatment of ascites. The therapy aims to reduce portal hypertension and improve ascitic fluid volume in patients with advanced liver disease.
Ascites Clinical Trials – Key Players
The EMR report for the ascites pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ascites therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ascites clinical trials:
- Wuhan YZY Biopharma Co., Ltd.
- Versantis AG
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Healthgen Biotechnology Corp.
- Grifols Shared Services North America Inc.
- Boehringer Ingelheim
- Noorik Biopharmaceuticals AG
- Resolution Therapeutics Limited
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ascites. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ascites drug candidates.
Drug: M701
M701 Bispecific Antibody, developed by Wuhan YZY Biopharma Co., Ltd., is under evaluation in a Phase III clinical trial to determine its efficacy and safety in treating malignant ascites caused by advanced epithelial solid tumors. This recombinant human-mouse chimeric antibody targets EpCAM on tumor cells and CD3 on T cells, facilitating immune-mediated tumor destruction. The study is examining M701’s ability to extend puncture-free survival and reduce fluid accumulation, aiming to improve overall patient outcomes.
Drug: VS-01
VS-01 is an innovative liposomal formulation developed by Versantis AG to treat patients with acute-on-chronic liver failure (ACLF) and ascites. In this Phase 2, multi-center, randomized, open-label study (UNVEIL-IT®), the drug is being evaluated for its efficacy, safety, and tolerability when administered intraperitoneally once daily for four days. The study is examining whether VS-01, combined with standard care, is improving clinical outcomes compared to standard therapy alone.
Key Questions Answered in the Ascites Pipeline Insight Report
- Which companies/institutions are leading the ascites drug development?
- Which company is leading the ascites pipeline development activities?
- What is the current ascites commercial assessment?
- What are the opportunities and challenges present in the ascites pipeline landscape?
- What is the efficacy and safety profile of ascites pipeline drugs?
- Which company is conducting major trials for ascites drugs?
- Which companies/institutions are involved in ascites collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in ascites?
The Ascites Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ascites. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ascites collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Ascites Market Size, Share Analysis and Forecast Report
Ascites Epidemiology Forecast
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Ascites
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Ascites
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Ascites: Epidemiology Snapshot
- 5.1 Ascites Incidence by Key Markets
- 5.2 Ascites – Patients Seeking Treatment in Key Markets
- 6 Ascites: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Ascites: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Ascites, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Ascites Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Ascites Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: M701
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Ascites Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: VS-01
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: SK-NK Injection
- 11.2.3 Other Drugs
- 12 Ascites Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: SIM0388
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: NK042
- 12.2.3 Drug: IFN-γ and CIK cells, Tcm cells or CAR T cells
- 12.2.4 Other Drugs
- 13 Ascites Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Ascites, Key Drug Pipeline Companies
- 14.1 Wuhan YZY Biopharma Co., Ltd.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Versantis AG
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Jiangsu Simcere Pharmaceutical Co., Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Healthgen Biotechnology Corp.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Grifols Shared Services North America Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Boehringer Ingelheim
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Noorik Biopharmaceuticals AG
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Resolution Therapeutics Limited
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
